Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real‐world review

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Transplant Infectious Disease

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1399-3062.2008.00325.xPMID 18627578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Graft vs host disease].

  2006cited by this paper
• Comparative analysis of a double primer PCR assay with plasma, leukocytes and antigenemia for diagnosis of active human cytomegalovirus infection in bone marrow transplant patients

  2005cited by this paper
• Quantitative real-time PCR with automated sample preparation for diagnosis and monitoring of cytomegalovirus infection in bone marrow transplant patients.

  2004cited by this paper
• Clinical aspects of CMV infection after stem cell transplantation.

  2004cited by this paper
• Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients.

  2003cited by this paper
• Monitoring Cytomegalovirus Infection in Adult and Pediatric Bone Marrow Transplant Recipients by a Real-Time PCR Assay Performed with Blood Plasma

  2003influential reference
• Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan

  2003cited by this paper
• Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

  2003cited by this paper
• Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation

  2003influential reference
• Definitions of cytomegalovirus infection and disease in transplant recipients.

  2002cited by this paper
• High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection.

  2002cited by this paper
• Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.

  2001cited by this paper
• Qualitative Plasma PCR Assay (AMPLICOR CMV Test) versus pp65 Antigenemia Assay for Monitoring Cytomegalovirus Viremia and Guiding Preemptive Ganciclovir Therapy in Allogeneic Stem Cell Transplantation

  2001cited by this paper
• Comparison of Quantitative Cytomegalovirus (CMV) PCR in Plasma and CMV Antigenemia Assay: Clinical Utility of the Prototype AMPLICOR CMV MONITOR Test in Transplant Recipients

  2000cited by this paper
• Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.

  2000cited by this paper
• Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.

  2000cited by this paper
• Quantitative Analysis of Cytomegalovirus (CMV) Viremia Using the pp65 Antigenemia Assay and the COBAS AMPLICOR CMV MONITOR PCR Test after Blood and Marrow Allogeneic Transplantation

  2000influential reference
• A Multisite Trial Comparing Two Cytomegalovirus (CMV) pp65 Antigenemia Test Kits, Biotest CMV Brite and Bartels/Argene CMV Antigenemia

  2000cited by this paper
• Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients.

  1999cited by this paper
• Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients.

  1999cited by this paper
• Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time

  1998cited by this paper
• Use of the cytomegalovirus (CMV) antigenemia assay for the rapid diagnosis of primary CMV infection in hospitalized adults.

  1998cited by this paper
• Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy.

  1997cited by this paper
• A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants.

  1997cited by this paper
• Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.

  1996cited by this paper
• Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.

  1996cited by this paper
• Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation.

  1995cited by this paper
• Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.

  1994cited by this paper
• Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease

  1993cited by this paper
• A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants

  1991cited by this paper
• Preemptive therapy in immunocompromised hosts.

  1991cited by this paper
• A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

  1991cited by this paper

• Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo‐HSCT): A systematic review, meta‐analysis, and meta‐regression analysis

  2019cites this paper
• Infectious, Autoimmune and Other Immune-Mediated Causes of Myelitis

  2017cites this paper
• Cytomegalovirus infection after solid organ transplantation

  2016cites this paper
• Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation

  2014cites this paper
• Stem Cell Therapy Literatures

  2013cites this paper
• Management of Antimicrobial Use in the Intensive Care Unit

  2012cites this paper
• Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.

  2011cites this paper
• Antiviral Chemoprophylaxis for Ocular Viral Infections in Hematopoietic Stem Cell and Bone Marrow Transplant Patients

  2011cites this paper
• Cytomegalovirus Infection in Transplantation

  2010cites this paper